These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial. Vollmer T; Henney HR Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891 [TBL] [Abstract][Full Text] [Related]
10. Fampridine-SR for multiple sclerosis and spinal cord injury. Hayes KC Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896 [TBL] [Abstract][Full Text] [Related]
11. Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial. Derakhshanrad N; Saberi H; Yekaninejad MS; Joghataei MT; Sheikhrezaei A J Neurosurg Spine; 2018 Jul; 29(1):97-107. PubMed ID: 29701561 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lithium carbonate treatment of chronic spinal cord injuries: a double-blind, randomized, placebo-controlled clinical trial. Yang ML; Li JJ; So KF; Chen JY; Cheng WS; Wu J; Wang ZM; Gao F; Young W Spinal Cord; 2012 Feb; 50(2):141-6. PubMed ID: 22105463 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. Grijalva I; Guízar-Sahagún G; Castañeda-Hernández G; Mino D; Maldonado-Julián H; Vidal-Cantú G; Ibarra A; Serra O; Salgado-Ceballos H; Arenas-Hernández R Pharmacotherapy; 2003 Jul; 23(7):823-34. PubMed ID: 12885095 [TBL] [Abstract][Full Text] [Related]
14. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. Morrow SA; Rosehart H; Johnson AM Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253 [TBL] [Abstract][Full Text] [Related]
15. Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Korenke AR; Rivey MP; Allington DR Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812 [TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. Vollmer T; Blight AR; Henney HR Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury. Hayes KC; Potter PJ; Hansebout RR; Bugaresti JM; Hsieh JT; Nicosia S; Katz MA; Blight AR; Cohen R Clin Neuropharmacol; 2003; 26(4):185-92. PubMed ID: 12897638 [TBL] [Abstract][Full Text] [Related]
18. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Casha S; Zygun D; McGowan MD; Bains I; Yong VW; Hurlbert RJ Brain; 2012 Apr; 135(Pt 4):1224-36. PubMed ID: 22505632 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455 [TBL] [Abstract][Full Text] [Related]
20. Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial. Lim JH; Muguet-Chanoit AC; Smith DT; Laber E; Olby NJ PLoS One; 2014; 9(12):e116139. PubMed ID: 25551385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]